Thalidomide as Salvage Therapy for Chronic Graft-Versus-Host Disease By Pablo M. Parker, Nelson Chao, Auayporn Nademanee, Margaret R. O‘Donnell, Gerhard M. Schmidt, David S. Snyder, Anthony S. Stein, Eileen P. Smith, Arturo Molina, Daniel E. Stepan, Ashwin Kashyap, Ina Planas, Ricardo Spielberger, George Somlo, Kim Margolin, K. Zwingenberger, K. Wilsman, Robert S. Negrin, Gwynn D. Long, Joyce C. Niland, Karl G. Blume, and Stephen J. Forman Thalidomide has been reported to be an effective agent for treatment of chronic graft-versus-host disease (CGVHD). To determine the efficacy of this agent in patients with refractory CGVHD a total of 80 patients who failed to respond to prednisone (PSE)orPSE and cyclosporine(CSA) were treated with thalidomide. Sixteen patients (20%) had a sustained response, 9 with a complete remission and 7 with a partial response. Twenty-nine patients (36%) had thalidomide discontinued because of side effects, which included sedation, constipation, neuritis, skin rash, and neutropenia. Side effects were reversible with drug discontinuation except for mild residual neuritis in one case. Rashes and neutropenia have not previously been reported as thalidomide side effects when used for CGVHD treatment. We conclude thalidomide is immunosuppressive and active in the treatment of CGVHD. A high incidence of reversible side effects limited dose intensity and reduced the number of patients who could benefit from treatment. 0 1995 by The American Society of Hematology. C PUVA had complete remissions. An additional 21 patients received thalidomide as part of primary therapy for newly diagnosed poor-risk CGVHD. Sevenof these had a complete response(CR).Toxicityappeared to be minimaland was limited to sedation and constipation, or sensory neuropathy reversible with discontinuation of medication. To extend the experience with this medication we have performed a phase I1 trial of thalidomide as salvage treatment for CGVHD refractory to primary therapy with PSE alone or in combination with CSA. This report summarizes results of treatment in 86 patients. HRONIC GRAFT-VERSUS-HOST disease (CGVHD) isthe principal cause ofmorbidity andnonrelapse mortality for patients reaching day100 after allogeneic bone marrow transplant (BMT). CGVHD occurs in 20% to 50% of these patients with mortality rates ranging from 20% to 70% depending on the associated risk factor^."^ The most prominent risk factor for poor outcome is progressive presentation (acute GVHD, which does not clear and evolves into CGVHD), which is consistently demonstrated in risk analyses by different groups.”‘ Concomitant thrombocytopenia or a combination of liver involvement with skin CGVHD with lichenoid skin histology have also been found to carry poor Theseanalyses reflect what has so far been achieved with treatment with standard available medication for CGVHD, namely prednisone (PSE), cyclosporine (CSA), and azathioprine. Thalidomidewas introduced as a sleeping pill butwas removed from the market because of its teratogenic effects. The discoverythat thalidomide has immunosuppressive propertiesled toitsusefor thetreatment of CGVHD. It was first reported in limited uncontrolled case reports with encouraging res~lts.’.~,~ Vogelsang et alx,9have performed the most extensivestudies on the use of this drugfor CGVHD both in a mouse model of the disease and subsequently in a phase I1 clinical trial. In this latter trial 7 of 23 patients with CGVHD refractory to primarytherapy with prednisone alone or with additional CSA, azathioprine, or From the Department of Hernuto1og.y and Bone Marrow Transplantation, City of Hope National Medical Center, Duurte; the Bone Murrow Trunsplant Program, Stanford UniversiQ Medical Center, Stunford, CA; and Grunenthal GMBH, Stolberg, Germany. Submitted March 23, 1995; accepted July 7, 1995. Supported by Grants No. POI-CA-40206,POI-CA-49605, and CA 33572 from the National Cancer Institute, Department of Health and Human Services, Bethesda, MD. Address reprint requests to Pablo M. Parker, MD, Department of’ Hemutology and Bone Marrow Transplantation, City of Hope Nutional Medical Center, 1500 E Duarte Rd, Duarte, CA 91010. The puhlimtion costs of this article were defrayed in part by page churge puyment. This article must therejbre be hereby marked “advertisement” in uccordance with 18 U.S.C. section 1734 solely to indicate this ,fact. 0 I995 by The American Sociely cf Hematology. 0006-497/~5/X609-0028$3.00/0 3604 PATIENTS AND METHODS All patients signed informed consent forms approvedby the Institutional Review Boards of the City of Hope National Medical Center and Stanford University. All female patients consented to take birth control pills while on thalidomide. Patients. BetweenSeptember 1987 andJanuary 1994, 86 paa total of 318 whodevelopedCGVHDwere tients(27%)from enrolledat both institutionsonthisstudy.Sixpatientswere not evaluable. The reasons were as follows: 4 died 5 to 13 days from starting thalidomide from interstitial pneumonia with severe refrac= l ) ; 1 patient tory CGVHD (n = 3), and from Candida sepsis (n responded but CSAhadalsobeenstartedforCGVHD 1 I days earlier; and 1 patient stopped thalidomide after 10 days of therapy because of anxiety over possible future side effects. The characteristics of the 80 evaluable patients arelisted in Table l . All patients had undergone allogeneic BMT from HLA identical siblingsor matched unrelated donors for hematologic malignancies, aplastic anemia, o r thalassemia. The preparative regimens varied according to disease and remission status and have been reported elsewhere.“”’ These included fractionated total body irradiation (1,320 rad) with either cyclophosphamide 120 m g k g or etoposide 60 mgkg, o r busulfan 16 m g k g with cyclophosphamide 120 mgkg. T depletion was not used. Acute GVHD prophylaxis varied over time according to institutionally active protocols and included CSA and PSE,CSNmethotrexate (MTX)/PSE, and Xomazyme/CSA/PSE.’ ’,IJ All patients on theseGVHDprotocolswerescheduled to continue CSA with or without PSE until day 180 after BMT. Diagnosis. The diagnosisofCGVHD was madeaccording to standard clinicalcriteria.’.’’.’” The diagnosis was confirmed histologicallyexcept in cases of mouth CGVHD or when liver or lung biopsies were necessary and the responsible physician did not feel coagulation parameters were safe. Twenty-two patients didnot have a biopsy to confirm the CGVHD histologically. All patientshadextensiveCGVHD(generalizedskin,liver histologic involvement with hyperbilirubinemia, or advanced Blood, Vol 86,No 9 (November l), 1995: pp 3604-3609 3605 THALIDOMIDE THERAPY FOR CGVHD Table 1. Characteristics of Patients With Chronic GVHD Total Agelmedian Diagnosis A ML remission First remission =First ALL remission First remission ZFirst CML CP AP/BC SAA MDS MPS Thalassemia sibling identical HLA MUD/MRD* Acute GVHD prophylaxis PSE/MTX CSA/PSE CSNMTWPSE CSNPSE/Xoma CSNPSEIATG Grade of acute GVHD 0-11 Ill-IV (range) 80 26/(6-50) 10 3 7 6 24 14 8 5 2 1 72 8 3 54 21 1 1 59 21 MUD, matched unrelated donor; MRD, matched related donor. changes, or multiple organ CGVHD) according to previously published criteria.2 Thirty-eight of the 80 patients also were classified as having poor prognostic features or high risk due to either thrombocytopenia, progressive presentation, or combined skin and liver CGVHD. Eligibility. Patients were eligible if they had progressing CGVHD after 1 month (n = 31) or stable but unimproved CGVHD (n = 40) after 2 months of PSE or PSElCSA treatment. Patients who responded to PSE or PSElCSA but flaredwhen these were tapered and required maintaining PSE at doses 220 mg/d were also eligible (n = 7). Patients were also eligible for thalidomide at PSE doses 5 2 0 mg/d if CGVHD was present and ongoing PSE treatment was contraindicated due to steroid related complications (aseptic hip necrosis, prior or concurrent fungal infections, or intolerance of cushingoid effects) (n = 2). Prior CSA therapy was not required but most patients had failed CSA (n = 67) as well and had thalidomide added to their existing PSWCSA treatment or were unable to receive further CSA because of CSA-related end-organ toxicity (n = 13) (Table 2). The target protocol eligibility dose of PSE 20 mg/d was chosen taking into account the long period of time these patients need to be on therapy for CGVHD with the potential for longterm steroid related complications. The median time on therapy for CGVHD before thalidomide was started was 4.5 months (range, 1 month to 3 '/z years). Thalidomide. Thalidomide was obtained either from Reiza do Nordeste (Sao Paulo, Brasil) or Grunenthal GMBH (Stolberg, Germany). Thalidomide was started at a dose of 100 mg orally four times a day and if no side effects were encountered was escalated to 200 and 300 mg four times a day. Drug levels were not evaluated for thalidomide. CSA levels were also not routinely done inall patients with CGVHD and their influence on outcome was therefore not analyzed in this trial. Patients were maintained on PSE and CSA when started on thalidomide. PSElCSA were then slowly tapered if CGVHD improved with addition of thalidomide. Responses. The frequency of follow-up for patients on thalidomide was determined by physician assesment of clinical need. Retrospective chart review was used to determine outcome. A complete response was classified as complete disappearance of all clinical manifestations of CGVHD. A partial response included a 50% improvement in objective parameters of CGVHD manifestations (extent of skin involvement, total bilirubin, pulmonary function tests (PIT) in bronchiolitis obliterans with organizing pneumonia [BOOP]). A response in oral CGVHD was more difficult to quantitate objectively but required symptomatic improvement as well as physician assessment of comparative improvement. Patients were considered to have no response if CGVHD progressed after 1 month or failed to improve after 3 months of thalidomide therapy. Only patients with sustained responses to thalidomide without reprogression were included among the responders. Patients who responded but then had to discontinue the drug due to side effects were considered treatment failures if the disease then progressed. All patients in this report have been on protocol more than 3 months. Survival was analyzed from the start of thalidomide therapy. RESULTS Response. Eighty patients are evaluable for response and toxicity. Their characteristics at transplant, acute GVHD proTable 2. Characteristics of Chronic GVHD at Study Entry Total CGVHD Site Mouth Skin Skin/mouth Liver (+/Fmouth) Liverlskin BOOP GI (+skin/mouth/liver) Thrombocytopenia Onset after BMT Progressive 3-6 m o 6-12 m o 12-24 m o >24 m o Prior treatment None PSE PSE/CSA PSE/CSNPUVA PSE/CSA/CTX Time from BMT to thalidomide start 3-6 m o 6-12 rno 12-24 mo >24 m o Extensive CGVHD* High risk (thrombocytopenia, progressive CGVHD, combined skin & liver CGVHD) Standard risk (all others) 80 15 9 15 15 12 9 5 29 23 20 25 10 2 1 12 62 4 1 Duration: median (range) 12mo 5 m o (1-26 mo) 4 m o (1-36 rno) 6 m o (2-36 m o ) 3%yr 19 29 14 18 80 38 42 * Limited, localized skin +/- hepatic dysfunction; extensive, generalized skin, advanced liver, or multiple organ CGVHD. 3606 PARKER ET AL Table 3. Summary of Results ~~ Response CR Patients ALL CGVHD High risk CGVHD* Standard risk CGVHD Mouth only Skin only Skinlmouth Liver +/- mouth Liver/skin Total CR 80 9 38 4 42 15 9 15 15 12 5 PR 3 16 (20%) 6 (16%) 5 1 10 (24%) 4 (24%) 0 (0%) 6 (40%) 5 (33%) 0 10%) 1(11%) - 1 5 5t - - - BOOP 9 GI (upper l)(lower 4) +/- liver/mouth/ lung skin 5 - + PR/ Percent 7 2 - - MR - 1 0 (0%) Survival Responders Nonresponders 16 64 9/9 (100%) 4/7 (57%) 13/16 (81%) 30/64 (47%) Abbreviation: MR. minor response (<PR). * W i t h thrombocytopenia, progressive CGVHD or combined skin/ liver CGVHD. t One mouth PR, skin no change. tients with gastrointestinal (GI) CGVHD were treated with thalidomide (Table 2). One had esophageal web syndrome. The other four had lower GI CGVHD. All had additional other organ involvement (skin/mouth/liver). They were placed on thalidomide with the intent of testing if the constipating effect of the drug would allow for absorption and a of diarrhea from therapeuticeffect even inthesetting CGVHD. None of these patients became responders. Fifteen of the 16 patients with refractory CGVHD who responded to thalidomide had failed PSE and CSA, one responding patient with mouth only CGVHD wason PSE only because of CSA intolerance. Among the 16 patientswho responded to thalidomide the median time to achieve a PR was 3 months (range 1 to 12 months). The median duration of thalidomide therapy was 16 months (range 4 months to 4'12 years). The median thalidomide dose was 200 mg four times daily (range, 100 mg three times a day to 400 mg four times a day). One patient with a PR for skidmouth CGVHD who had no side effects with the 300 mg three times a day dose was dose escalated to 400 mg four times a day. All patients initially remained on PSE or PSE/CSA in addition to the thalidomide until a response was achieved and were then sequentiallytapered off allthree drugsover several months. The choice of drug to taper first was by physician preference althoughPSE wasusuallytapered first. Six of the 16 responders remain off all immunosuppressive medications 8 to 36 months after discontinuing thalidomide. Seven additionalrespondingpatientsremainontaperedthalidomide or PSE and/or CSA for a median of 3 years (range, 1 to S years) from thestart of thalidomide therapy. Three additional patients with a sustained response to thalidomide died while still on tapered doses of thalidomide, PSE/CSA from infectious complications of CGVHD (two dueto pneumonia and one fromencephalitis) 6, 16, and 2.5 months from the start of thalidomide treatment. An additional eight patients were improving on thalidomide but had to discontinue the drug becauseof side effects and then subsequentlyprogressed.Theywere countedas treatment failures. Five had mouth CGVHD only, one had combinedskidmouth,onecombinedmouth, esophageal web, and bronchiolitis, and one liver involvement. All flared again after discontinuation of thalidomide. Six remain with persistentunimproved CGVHD on PSE/CSA 1 to 5 years after discontinuing thalidomide. Two have hada PR, one with additional treatment, which included photopheresiswith phylaxis regimen, and gradeof subsequent acute GVHDare summarized in Table l . The status of their CGVHD at entry to the thalidomide protocol is summarized in Table 2. Sixteen of 80 patients (20%) had asustained response (Table 3). Nine patients had a CR and seven a partial response (PR). Overall 6 (16%) of 38 patients with high-risk CGVHD and 10(24%) of 42 with standard-risk CGVHD respondedtothalidomide(Table 4). The high-risk group included 2 of 23 patients with progressive CGVHD ( s k i d mouthwith thrombocytopenia [n = l] and liver [n = l]) and 4 with thrombocytopenia with mouth (n = 1) or liver (n = 3) involvement. None of 12 patientswith combined skin and liver CGVHD responded. Four of 15 patients with mouth only CGVHD and 5 of 14 with combined skin and mouth CGVHD responded. One of these latter patients had a PR for severe sclerodermatous skin involvement. No other patienttreated for severe sclerodermatous skin involvement (isolated or with other organ involvement) responded. One other patient with combined mouth and skin CGVHD had a PR for the mouth CGVHD on thalidomide without improvement of skin manifestations. Table 4. Toxicitv of Thalidomide The latter then improved on additional PUVA therapy. Five with or without associated mouth of 15 with liver CGVHDTotal Sedation CGVHD (totalbilirubin median 11.6, range 4.9 to 25.1) Stopped treatment responded. One other patientwith a PR for mouth CGVHD Total Constipation/nausea also had BOOP with PFT at 60% of pre-BMT values and Stopped treatment was oxygen dependentTotal atstart of thalidomide. Her PFT only Neuritis Stopped treatment improved by 20% on thalidomide and did not meet criteria for a PR, but she became oxygen independent and Total her exer-rash New skin Stopped treatment cise tolerance improved. Unfortunately, she died ofan acute Total Neutropenia encephalitis of presumed viral origin after remaining 2 years Stopped treatment on thalidomide treatment. None of the other eight patients Stoppedtreatment-alltoxicitiesTotal with BOOP treated with thalidomide responded. Five pa- 32 (40%) 7 24 (30%) 3 3 (5%) 3 13 (16%) 6 14 (18%) 10 29 (36%) THALIDOMIDE THERAPY FOR CGVHD PSWCSA and the other by continuing longer treatment with PSWCSA. Of note one of the patients entered on this protocol had not received any CGVHD treatment for l year before starting thalidomide (Table 2). She had sclerodermatous skin CGVHD with contractures and had developed a psychotic episode after 6 months of combined PSWCSA treatment. Both were tapered off and she remained with persistent CGVHD off therapy until thalidomide became available 1 year later. She died 2 months after starting thalidomide from CGVHD-related complications and was considered a treatment failure. Toxicity. There was significant difficulty in maintaining patients on this medication because of a high frequency of both patient intolerance of sedation and bowel distension and additional side effects requiring drug discontinuation. Previous reports of side effects when using thalidomide for CGVHD have listed sedation and constipation as the most common with tachyphylaxis as treatment continues leading to adequate patient tolerance? Sensory neuropathy has also been reported as a less frequent complication but its appearance warrants taking the patient permanently off medication." We also encountered frequent initial sedation and constipation (Table 4). However, not all patients adapted with time and seven patients discontinued the drug due to persistent sedation even with dose reduction. Although constipation was less problematic resolving with stool softeners, the bowel distension caused by thalidomide led to stopping medication in three patients because of abdominal discomfort with nausea and vomiting. Symptoms of sensory neuropathy led to discontinuation of medication in three patients. One patient still has neuropathic symptoms 4 months after stopping thalidomide. Neuropathy resolved in the other two within 2 months of stopping medication. We also encountered two additional side effects. The first was development of a new skin rash (in 4 patients) clinically suggestive of CGVHD (when none had beenpreviously present) or flare of a pre-existing skin GVH rash (in 9 patients) within 4 weeks of starting treatment. PSWCSA doses had not yet been tapered in four (2 with and 2 without preexisting skin CGVHD) of these patients when the rash developed or flared. Skin biopsies were done in 5 of these 13 patients and showed histologic changes suggestive of CGVHD in all cases. In all cases improvement or resolution of skin rash occurred as PSE doses were increased at the same time that thalidomide was held. Two patients with skin CGVHD were rechallenged with thalidomide when the skin rash had improved and flaredwith the second challenge. Four other patients were not restarted on thalidomide after developing a rash due to physician andor patient reluctance to restart therapy due to this side effect. One patient who was started on thalidomide for skin (localized to face and upper torso) and mouth CGVHD developed a severe Stevens-Johnson like syndrome with erythroderma with bullous lesions and conjunctival and mouth mucosal involvement 2 weeks after starting therapy. His PSWCSA had not yet been tapered. He required hospitalization and high-dose steroids with resolution of the acute skin changes but persistence of 3607 his prior CGVHD baseline skin lesions. He subsequently died from CGVHD progression with BOOP but without new skin lesions. Seven other patients were restarted on thalidomide after the skin rashes improved and did not reflare.None of these became responders and were therefore eventually takenoff medication because of CGVHD progression. Among the 13 patients who developed skin rashes with the start of thalidomide treatment there was a higher incidence of two poor risk factors. Six (46%) had prior thrombocytopenia and seven (54%) had progressive presentation of CGVHD. This compared with the 67 patients who did not develop skin rashes in which 23 (34%) had thrombocytopenia and 16 (24%) had progressive CGVHD. The third poor prognostic risk factor, combined skidiver CGVHD, was not more frequent in this group with only 1 of 13 (8%) in those developing a skin rash as opposed to 1 1 of 67 (16%) in those who did not. The second additional unexpected toxicity was neutropenia (Table 4). This occurred in 14 patients at a median of 4 weeks (range 1 to 11 weeks) from starting therapy without affecting red blood cell (RBC) and platelet counts. The median pre-thalidomide white blood cell (WBC) count was 4.2 X IO9& (range, 1.6 to 6.4) with a median WBC nadir of 0.9 X IO9& (range, 0.3 to 2.0). The median thalidomide dose at which neutropenia developed was 200 mg four times a day (range, 50 mg twice a day to 300 mg four times a day). The neutropenia usually resolved within 1 month of discontinuing thalidomide (except in three patients who died between 3 weeks and 1 'l2months from starting thalidomide due to refractory rapidly progressing CGVHD). As there are other causes of neutropenia in BMT patients, especially with CGVHD, six patients were rechallenged with thalidomide and again became neutropenic. The neutropenia was the direct reason for discontinuing thalidomide in 10 of 14 patients. In the other four patients, one had associated neuropathy and two others discontinued use due to refractory CGVHD. Only one patient who developed neutropenia remained on treatment. He had responded to thalidomide and was rechallenged and developed recurrent neutropenia, but was able to remain on 50% doses with intermittent G-CSF. Among the 14patients who developed neutropenia 12 (86%) had thrombocytopenia, 8 (57%) had progressive CGVHD, and 3 (21%) had combined skidiver CGVHD. This compared with 14 (21%) with thrombocytopenia, 13 (20%) with progressive CGVHD, and 9 (14%) with combined skidiver CGVHD in the 66 patients who did not have neutropenia. Survival and causes of death. Forty-three of the 80 (53%) treated patients are alive. Thirteen of sixteen (81%) patients who responded are alive with a median follow-up of 2 years/8 months (range, 6 months to 5 years). Thirty of 64 (47%) who did not respond survive with a median survival of l year12 months (range, 1 month to 7 years14 months). Thirty-seven patients died. Twenty-seven died from organ failure with refractory CGVHD: 11 with hepatic failure, 6 with interstitial pneumonitis or respiratory failure associated with severe sclerodermatous or liver CGVHD, 10 with bronchiolitis obliterans. An additional 5 patients died from infection: two pneumonias, one disseminated aspergillus, one brain abscess, organism unidentified, and one encephalitis 3608 of presumed viral origin. One patient died from a cerebrovascular accident, one committed suicide3 months off thalidomide with persistent liver CGVHD. Three patients died at home. Two were on thalidomide with severe sclerodermatous CGVHD. One was off thalidomide for 10 months with persisting CGVHD and severe immunodeficiency with disseminated mycobacterium avium-intracelulare infection. There were no relapses in these 80 patients with refractory CGVHD. PARKER ET AL we were impressed with the timing of the rash occumng soon after starting the drug, even in patients in whom PSEl CSAhad not yet beentapered orwho had had noskin CGVHD before starting thalidomide. In addition, two patients who wererechallengedhadskin flare ups asecond time. Two brief references to skin rashes as drug side effects in patients treated with thalidomide are noted in a review on the use of the drug for leprosy reaction.Ix." It is noteworthy that the patients in our study who developed skin rashes on thalidomide had more advanced CGVHD. It is possible that DISCUSSION in some patients thalidomide may be initially causing adrugrelated skin reaction, which maythen be exacerbating underThese resultsconfirm thalidomidehas activity against lying subclinical or pre-existing skin CGVHD, just ab sun CGVHD, which has failed treatment with PSE or PSElCSA. exposure has beenreported to flareskinCGVHD.' This Sixteen (20%) of 80 patients in this series had a sustained would explain the finding of histologic GVHD when skin response. When looking at prognostic subgroups more rebiopsies were performed in these cases. sponses wereseen in patients with standard-risk CGVHD Neutropeniahas not beenreported as a sideeffect of (10 of 42) than in those with high-risk disease (6 of 38). thalidomide inthetransplantliterature. There is a report There was no particular riskprofile that predictedwhich from the World Health Organization on a tendencyto neutropatients would respond except that responses were rare in those with CGVHD, which has had poor outcome with stan- penia in leprosy patients treated with thalidomide.*" We observed a frequent association (14 of 80 patients) of neutrodard available treatment such as BOOP, combined skin and penia with the start of thalidomide therapy. In these cases it liverCGVHD,andprogressive presentation. Wedidsee was not possible to differentiate the neutropenia from that responses in patients with thrombocytopenia as the only asoccurring as a complication of CGVHD where multiple facsociated poor prognostic factor. Mostof the responses were tors including infection, folatehtritional deficiency. or drug in patients with isolated mouth or liver CGVHD and skin effects in addition to the probableautoimmune effects of involvementthatdid not includesevere sclerodermatous GVHD on marrow function may have been active."." Howmanifestations. Thalidomide therapy was a new beneficial ever, again the timing of this complication, occurring in the treatment modality for these patients since over half had a first weeks after thalidomide was started in patients without CR for CGVHD, which up to that point was refractory to prior neutropenia, and the recurrence of neutropenia on retreatment and all were able to either discontinue or significhallenge with thalidomide in six patients suggests this was cantly reducePSE treatment requirements. An additional a drug-related effect. Patients treated with thalidomide for eight (10%) patientswere improving but had to discontinue CGVHD should have theirblood counts frequentlymonithe drug due to side effects followed by progression. Theretored during the first weeks of therapy. fore, they did notbenefit from treatment. Although they were We did not find thalidomide to be useful for treatment of notincluded in our listofresponders,their improvement the majority of patients with CGVHD, which was prohas significance in emphasizing that the immunosuppressive gressing after failing PSEKSA. We may have been limited properties of thalidomide may be better than what is sugby the high incidence of side effects (especially neutropenia gested by our limited 20% response rate, and that the diffiand skin rashes) in this group, which did not allow for dose culty in dose escalating or maintaining patients on the mediintensity. We did not measure drug levels in our patients but cation due to side effects may bea major problem with this the majority did nottolerateescalatingthalidomide doses drug in the treatment of CGVHD. above 400 to 600 mgld, which was below the target doses Atotalof 29 (36%) of the 80 patients were takenoff of 800 to 1,200 mgld. Vogelsang et al used doses of 800 to treatment because of side effects. Ten of thesewere unableto 1,600 mgld to reachtargettherapeuticserum levels." It is continue treatment due tosedation or constipatiotdabdorninal possible that if thalidomide were used earlier as part of first distension and three due to neuropathy. An additional16 line therapy, patients would tolerate dose intensive therapy patients had skin rashes or neutropenia, which required disbetter with animproved response rate. Vogelsang et al' continuing medication. Sedation, constipation, and neuropatreated patients with poor risk features with thalidomide as thy are well-described complications of thalidomide. In a part of first line therapy in combination with PSElCSA in report by Vogelsang et al,9 sedation and constipation didnot theirclinical trial. This led to anexcellentresponserate apparentlylead to difficultyincontinuingtreatment since (7 of 21 patients had a CR) and improved survival (48%) compared with historical controls of However, the they seemed to predominate only in the first weeks of therhistorical controls received PSEorPSEhzathioprine and apy. Only 6 of 43 patients were withdrawn from that study did not uniformlyreceive CSA. Sullivanet a12.'4.25found because of drug side effects (4 because of neuropathy and combined PSElCSA also improvedsurvival to an equivalent 2 because of noncompliance with medication). level of 50% compared with 26% overPSE or CSAas New skin rashes were not reported by Vogelsang et al. single agents for CGVHD patients with poor risk defined by New skin rashes or exacerbation of previously existing skin thrombocytopenia. Therefore, the trueresponse and survival CGVHD occurred in a significant number of our patients benefit of adding thalidomide to PSElCSA as first line ther(13 of 80 or 16%) (Table4). The simplest explanationwould apy for CGVHD needs to be studied in a randomized trial. be that these rashes represented flare a of CGVHD. However, THALIDOMIDE THERAPY FOR CGVHD An additional decision stemming from the possibility that earlierintroduction of thalidomide in CGVHD treatment may improve efficacy would be to include it in CGVHD prophylaxis. We are currently conducting a placebo-controlled randomized trial of thalidomide added to CSA for CGVHD prophylaxis in an adult BMT population. REFERENCES I. Vogelsang GB, Wagner JE: Graft-versus-host disease, in Forman SJ ( 4 ) : Hematology/Oncology Clinics of North America, v01 4:3. Philadelphia, PA, Saunders, 1990, p 625 2. Sullivan KM: Graft-versus-host disease, in Forman SJ, Blume KG, Thomas ED (eds): Bone Marrow Transplantation. Boston, Blackwell Scientific, 1994, p 353 3. Sullivan KM, Mori M, Witherspoon R, Sanders J, Appelbaum FR, Storb R: Alternating day cyclosporine and prednisone (CSP/ PRED) treatment of chronic graft-versus-host disease (GVHD): Predictors of survival. Blood 76:568a, 1990 (abstr) 4. Wingard JR, Piantadosi S, Vogelsand GB, Farmer ER, Jabs DA, Levin LS, Beschomer WE, Cahill RA, Miller DF, Harrison D, Sara1 R, Santos GW: Predictors of death from chronic graft versus host disease after bone marrow transplantation. Blood 74: 1428, 1989 5. Lim SH, McWhannell A, Vora AJ, Boughton BJ: Successful treatment with thalidomide of acute graft-versus-host disease after bone-marrow transplantation. Lancet 1:117, 1988 6. Heney D, Norfolk DR, Wheeldon J, Bailey CC, Lewis IJ, Barnard DL: Thalidomide treatment for chronic graft-versus-host disease Br J Haematol 78:23, 1991 7. Wood P, Proctor SJ: The potential use of thalidomide in the therapy of graft-versus-host disease-A review of clinical and laboratory information. Leuk Res 14:395, 1990 8. Vogelsang GB, Hess AD, Friedman U,Santos GW: Therapy of chronic graft-v-host disease in a rat model. Blood 74:507, 1989 9. Vogelsang GB, Evan MD, Farmer ER, Hess AD, Altamonte V, Beschorner WE, Jabs DA, Corio RL, Levin LS, Colvin OM, Wingard JR, Santos GW: Thalidomide for the treatment of chronic graft-versus-host disease. N Engl J Med 326:1055, 1992 IO. Shank B, Chu F, Dinsmore R, Florence CH, Kapoor N, Kirkpatrick D, Teitelbaum H, Reid A, Bonfiglio P, Simpson L, O’Reilly RJ: Hyperfractionated total body irradiation for bone marrow transplantation. Results in seventy leukemia patients with allogeneic transplants. Int J Radiat Oncol Biol Phys 9:1607, 1983 1 I . Blume KG, Forman SJ, O’Donnell MR, Doroshow JH, Krance RA, Nademanee AP, Snyder DS, Schmidt GM, Fahey JL, Metter GE, Hill LR, Findley DO, Sniecinski IJ: Total body irradiation and high-dose etoposide: A new preparatory regimen for bone marrow transplantation in patients with advanced hematologic malignancies. Blood 69:1015, 1987 12. Tutschka PJ, Copelan EA, Klein JP: Bonemarrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. Blood 70:1382, 1987 3609 13. Forman SJ, Blume KG, Krance RA, Miner PJ, Metter GE, Hill LR, O’Donnell MR, Nademanee AP, Snyder DS: A prospective randomized study of acute graft-v-host disease in 107 patients with leukemia: Methotrexate/prednisone v cyclosporine Nprednisone. Transplant Proc 19:2605, 1987 14. Chao NJ, Schmidt GM, Niland JC, Amylon MD, Dagis AC, Long GD, Nademanee AP, Negrin RS, O’Donnell MR, Parker PM, Smith EP, Snyder DS, Stein AS, Wong RM, Blume KG, Forman SJ: Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versushost disease N Engl J Med 329:1225, 1993 15. Saurat JH: Cutaneous manifestations of graft-versus-host disease. Int J Dermatol 4:249, 1981 16. Schubert MM, Sullivan KM: Recognition, incidence, and management of oral graft-versus-host disease. NCI Monogr 9: 135, I990 17. Ochonisky S , Verroust J, Bastuji-Garin S, Gherardi R, Revuz J: Thalidomide neuropathy incidence and clinicoelectrophysiologic findings in 42 patients. Arch Dermatol 130:66, 1994 18. Lakeman P, Smith WC: Thalidomide in leprosy reaction. Lancet 343:432, 1994 19. Grosshans MD, Genevieve I: Thalidomide therapy for inflammatory dermatoses. Int J Dermatol 23:598, 1984 20. Iver CG, Languillon I, Ramanujam G , Sundaresan T WHO coordinated short term double blind trial with thalidomide in the treatment of acute lepromatous reactions in male lepromatous patients. Bull Wld Hltb Org 45:719, 1971 21. Hirabayashi N: Studies on graft versus host (GvH) reactions. I. Impairment of hemopoietic stroma in mice suffering from GvH disease. Exp Hematol 9:101, 1981 22. Atkinson K, Nome S, Chan P, Zehnwirth B, Downs K, Biggs J: Hemopoietic progenitor cell function after HLA-identical sibling bone marrow transplantation: Influence of chronic graft-versus-host disease. Int J Cell Cloning 4:203, 1986 23. Peralvo J, Baeigalupo A, Pittaluga PA, Occhini D, Van Lint MT, Frassoni F, Nardelli E, Trasino A, Pantarotto M, Marmont AM: Poor graft function associated with graft-versus-host disease after allogeneic marrow transplantation. Bone Marrow Transplant 2:279, 1987 24. Sullivan KM, Witherspoon RP, Storb R, Weiden P, Flournoy N, Dahlberg S , Deeg HJ, Sander JE, Doney KC, Appelbaum FR, McGuffin R, McDonald GV, Meyer J, Schubert MM, Gauvrequ J, Shulman HM, Sale GE, Anasetti C, Loughran TP, Strom S, Nims J, Thomas ED: Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease: Prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation. Blood 72:546, 1988 25. Sullivan KM, Witherspoon RP, Storb R, Deeg HJ, Dahlberg S, Sanders JE, Appelbaum FR, Doney KC, Weiden P, Anasetti C, Loughran TP, Hill R, Shields A, Yee G , Shulman H, Nims J, Strom S , Thomas ED: Alternating-day cyclosporine and prednisone for treatment of high-risk chronic graft-v-host disease. Blood 72:555, 1988
© Copyright 2024